DIRS.INFO The most relevant business & tech news

☆ Netflix's 'Joy' tells the story of the first IVF baby. Here's where Louise Brown is now.
▼ + stars: | 2024-11-21 | by ( Eammon Jacobs | ) www.businessinsider.com time to read: +3 min

Here's where Louise Brown, the first IVF baby, is now. "Joy" is about the British doctors who helped conceive the first baby using IVF treatment in the late 1970s. Louise Brown was born in 1978Louise Brown at the Science Museum in London. Leon Neal/Getty ImagesLouise Joy Brown was born on July 25, 1978, with her middle name giving the Netflix movie its title. Unfortunately, Jean Purdy died at the age of 39 and I did not know her."

Persons: Bill Nighy, Thomasin McKenzie, James Norton, Here's, Louise Brown, Patrick Steptoe, Jean Purdy, Robert Edwards, Guillermo del Toro's, Steptoe, Purdy, Edwards, Lesley, John Brown, implanting Brown, Leon Neal, Getty, Louise Joy Brown, She's, Brown, Patrick, Bob, Bob Edwards Organizations: Netflix, Centre, New York Times, Browns, Science Museum, Bristol's Old, Bourn Hall Clinic Locations: Oldham, Manchester, England, London, Bristol, Cambridgeshire

☆ 'Mag 7' leads reversal — plus, we're adding a new stock to our Bullpen watchlist
▼ + stars: | 2024-11-19 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Next, we are going outside our current holdings and adding drugmaker Bristol Myers Squibb to the Bullpen, our watchlist of stocks that could join the portfolio. New Jersey-based Bristol Myers is in the midst of a transition phase under the leadership of new CEO Chris Boerner. Companies reporting earnings before the open Wednesday include Club stock TJX Companies , along with Target , Williams-Sonoma , and ZIM Integrated . THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Robert F, Kennedy Jr, Kennedy, Donald Trump, Wall, Eli Lilly, Bristol Myers, Chris Boerner, Boerner, Karuna, we'll, Stanley Black, Decker, Jim Cramer's, Jim Organizations: CNBC, ., Club, Nvidia, Dow Jones, of Health, Human Services, Senate, Bristol Myers Squibb, Bristol, pharma, Karuna Therapeutics, FDA, JPMorgan, Keysight Technologies, TJX Companies, Target, Williams, ZIM, Jim Cramer's Charitable Locations: New Jersey, U.S, Sonoma

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +7 min

RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance

Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol

☆ Britain to invest 300 million pounds in AI supercomputing
▼ + stars: | 2023-11-01 | by ( ) www.reuters.com time to read: +2 min

British Prime Minister Rishi Sunak delivers a speech on AI at Royal Society, Carlton House Terrace on October 26, 2023 in London, England. Funding for the "AI Research Resource" will be increased to 300 million pounds ($363.57 million) from a previously announced 100 million pounds, the government said at an AI safety summit aimed at charting a safe way forward for the rapidly evolving technology. "Frontier AI models are becoming exponentially more powerful," British Prime Minister Rishi Sunak said on social media platform X. "This investment will make sure Britain’s scientific talent have the tools they need to make the most advanced models of AI safe." The machines, which will be running from summer next year, will be used to analyse advanced AI models to test safety features, as well as to drive breakthroughs in drug discovery and clean energy, the government said.

Persons: Rishi Sunak, Peter Nicholls, Bristol's, Kylie MacLellan, Kirsten Donovan Organizations: British, Royal Society, Carlton, Terrace, REUTERS, Nvidia, Hewlett Packard Enterprise, Dell, SME, Thomson Locations: London, England, Britain, Cambridge, Bristol

☆ Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
▼ + stars: | 2023-10-09 | by ( Michael Erman | ) www.reuters.com time to read: +3 min

REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsOct 8 (Reuters) - Bristol-Myers Squibb (BMY.N) on Sunday said it will acquire cancer drugmaker Mirati Therapeutics (MRTX.O) for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade. Bristol will pick up Mirati's portfolio drugs that target the genetic drivers of specific cancers including its lung cancer drug, Krazati, which was approved in December. The company said that it will buy Mirati for $58 per share in cash, or around $4.8 billion. Mirati has around $1.1 billion in cash on hand, so "we're paying essentially $3.7 billion enterprise value...we think with that we've gotten a very attractive deal," Lenkowsky said. Last year, Bristol acquired drug developer Turning Point Therapeutics for $4.1 billion in cash to help bolster its arsenal of cancer drugs.

Persons: Bristol Myers, Dado Ruvic, Adam Lenkowsky, Mirati, we've, Lenkowsky, Chris Boerner, Giovanni Caforio, Boerner, Lavanya Ahire, Lisa Shumaker, Diane Craft, Andrea Ricci, Michael Perry Organizations: Bristol, Bristol Myers Squibb, REUTERS, Myers Squibb, Therapeutics, U.S . Food, Drug Administration, Bristol Myers, Thomson Locations: Bristol, U.S, New York

☆ Cramer's Lightning Round: Super Micro Computer is not a buy
▼ + stars: | 2023-05-30 | by ( Julie Coleman | ) www.cnbc.com time to read: +3 min

Stock Chart Icon Stock chart icon Bowlero's year-to-date stock performance. Stock Chart Icon Stock chart icon Corteva's year-to-date stock performance. Stock Chart Icon Stock chart icon Telus's year-to-date stock performance. Stock Chart Icon Stock chart icon Super Micro Computer's year-to-date stock performance. Stock Chart Icon Stock chart icon Upstart's year-to-date stock performance.

Persons: Myers, Smith, Neidorff, That's, It's Organizations: Bristol, Myers Squibb, Telus, Mobile, Verizon, Carrier Locations: California, Bristol, Myers, Europe

Search resuls for: "Bristol's"

7 mentions found